About this trial
This study aims to utilize a randomized controlled trial in asymptomatic hyperuricemic individuals to clarify the effects of four probiotic strains including Lactobacillus acidophilus on serum uric acid levels, pathways of uric acid synthesis, degradation and excretion, hyperuricemia-induced oxidative stress and chronic inflammatory responses, uric acid-related metabolites, gut microbiota composition and diversity.
Eligibility criteria
Qualifiers
Men and women aged 18-65;
Residents who have lived in Guangdong for more than one year;
According to the "Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia-Related Diseases (2023 Edition)", asymptomatic HUA is defined as a fasting serum uric acid level >420 umol /L and no history of gout symptoms such as gouty arthritis;
Consent to be randomly assigned to the intervention or control group;
Disqualifiers
Secondary HUA caused by disease or drugs;
Within 3 months before participating in the study, or currently taking drugs that affect uric acid metabolism, such as azathioprine, thiazide diuretics, prednisone, etc., and unwilling to stop taking them during the study;
Taking or currently taking medication for gout within 3 months before participating in the study and unwilling to stop taking it during the study;
Abnormal liver function (AST or ALT levels are more than 3 times the upper limit of normal), abnormal renal function (glomerular filtration rate less than 60mL/min/1.73m²);
Trial design
Treatments tested in this trial
- Probiotic
- Placebo
Treatment groups
Sponsors and collaborators
Sun Yat-sen University
Lead sponsor
The Eighth Affiliated Hospital of Sun Yat-sen University
Collaborator